MA31326B1 - Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds - Google Patents
Pyrimidine-hydrazides en tant qu'inhibiteurs de pgdsInfo
- Publication number
- MA31326B1 MA31326B1 MA32299A MA32299A MA31326B1 MA 31326 B1 MA31326 B1 MA 31326B1 MA 32299 A MA32299 A MA 32299A MA 32299 A MA32299 A MA 32299A MA 31326 B1 MA31326 B1 MA 31326B1
- Authority
- MA
- Morocco
- Prior art keywords
- hydrazide
- pyrimidine
- pgds inhibitor
- compound
- pgds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Cette invention concerne un composé dans lequel r1, r2, r3, r4 et l1 sont tels que définis ici, une composition pharmaceutique comportant les composés et l'utilisation du composé pour traiter des troubles allergiques et/ou inflammatoires, en particulier des troubles tels que la rhinite allergique, l'asthme et/ou une maladie pulmonaire obstructive chronique (copv).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90917107P | 2007-03-30 | 2007-03-30 | |
PCT/US2008/058347 WO2008121670A1 (fr) | 2007-03-30 | 2008-03-27 | Composés d'hydrazide de pyrimidine en tant qu'inhibiteurs de pgds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31326B1 true MA31326B1 (fr) | 2010-04-01 |
Family
ID=39494539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32299A MA31326B1 (fr) | 2007-03-30 | 2009-10-22 | Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds |
Country Status (25)
Country | Link |
---|---|
US (1) | US8258130B2 (fr) |
EP (1) | EP2142516B1 (fr) |
JP (1) | JP5427769B2 (fr) |
KR (1) | KR20090125852A (fr) |
CN (1) | CN101646656B (fr) |
AR (1) | AR065874A1 (fr) |
AU (1) | AU2008232771B2 (fr) |
BR (1) | BRPI0809974A2 (fr) |
CA (1) | CA2682629C (fr) |
CL (1) | CL2008000911A1 (fr) |
DK (1) | DK2142516T3 (fr) |
ES (1) | ES2400622T3 (fr) |
IL (1) | IL200898A (fr) |
MA (1) | MA31326B1 (fr) |
MX (1) | MX2009009443A (fr) |
MY (1) | MY154895A (fr) |
NZ (1) | NZ579892A (fr) |
PA (1) | PA8774101A1 (fr) |
PE (1) | PE20090552A1 (fr) |
PT (1) | PT2142516E (fr) |
RU (1) | RU2464262C2 (fr) |
SG (1) | SG179437A1 (fr) |
TW (1) | TWI430994B (fr) |
WO (1) | WO2008121670A1 (fr) |
ZA (1) | ZA200906082B (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ579892A (en) | 2007-03-30 | 2012-03-30 | Sanofi Aventis | Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors |
MX2010002258A (es) * | 2007-08-27 | 2010-04-22 | Helicon Therapeutics Inc | Compuestos terapeuticos de isoxazol. |
HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
MY154000A (en) | 2008-09-22 | 2015-04-30 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
JP2012511575A (ja) * | 2008-12-12 | 2012-05-24 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのアザインドール誘導体 |
EP2266562A1 (fr) * | 2009-06-23 | 2010-12-29 | Centre National de la Recherche Scientifique | Utilisation de dérivés des indoles pour le traitement du cancer |
US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
CA2776242C (fr) | 2009-10-08 | 2014-09-02 | Sanofi | Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds |
AT509045B1 (de) | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
EP2576536B1 (fr) | 2010-06-01 | 2016-09-14 | The University of Queensland | Inhibiteurs de la prostaglandine d2 synthase hématopoïétique |
EA201391626A1 (ru) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
CA2856453C (fr) | 2011-11-29 | 2020-10-13 | Syngenta Participations Ag | Derives de triazinone insecticides |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
PL3033336T3 (pl) | 2013-08-14 | 2018-11-30 | Kalvista Pharmaceuticals Limited | Inhibitory kalikreiny w plaźmie |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
EP3165093A1 (fr) | 2015-11-05 | 2017-05-10 | Basf Se | Oxadiazoles substitués pour lutter contre des fongus phytopathogènes |
BR112018012469B1 (pt) | 2015-12-17 | 2020-11-24 | Astex Therapeutics Limited | compostos quinolina-3-carboxamidas como inibidores da h-pgds, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos. |
HUE049918T2 (hu) | 2016-05-31 | 2020-11-30 | Kalvista Pharmaceuticals Ltd | Pirazol-származékok mint plazma kallikrein inhibitorok |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
UY37764A (es) | 2017-06-13 | 2019-01-02 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) |
IL274557B1 (en) | 2017-11-29 | 2024-05-01 | Kalvista Pharmaceuticals Ltd | Dosage forms containing a plasma kallikrein inhibitor |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
CA3085293A1 (fr) | 2017-12-13 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Pyridines fusionnees agissant en tant qu'inhibiteurs de h-pgds |
JP2022506850A (ja) | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
WO2021256569A1 (fr) * | 2020-06-19 | 2021-12-23 | 佐藤製薬株式会社 | Composés cycliques condensés qui inhibent la h-pgds |
CN112375027B (zh) * | 2020-12-07 | 2023-03-31 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
WO2023113023A1 (fr) * | 2021-12-17 | 2023-06-22 | 佐藤製薬株式会社 | Dérivé d'azaindole inhibant h-pgds |
CN116514769B (zh) * | 2022-01-21 | 2024-02-27 | 中国药科大学 | 4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6143173A (ja) * | 1984-08-06 | 1986-03-01 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体およびその製法 |
JPS61140568A (ja) * | 1984-12-14 | 1986-06-27 | Mitsui Petrochem Ind Ltd | キナゾリン誘導体及びそれを有効成分とする血圧降下剤 |
US5176132A (en) | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
RU2343148C2 (ru) * | 2002-02-01 | 2009-01-10 | Райджел Фармасьютикалз, Инк | Соединения 2,4-пиримидиндиаминов и их применение |
KR20050035885A (ko) | 2002-08-16 | 2005-04-19 | 아벤티스 파마슈티칼스 인크. | 마이크로솜성 프로스타글란딘 e 신타제 또는 조혈성 프로스타글란딘 d 신타제의 활성을 감소시키는 능력에 대해 화합물 또는 제제를 검정하는 방법 |
GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
GT200500284A (es) * | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
JP2007051121A (ja) * | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンd合成酵素を阻害するピリミジン化合物 |
JP2010513357A (ja) * | 2006-12-22 | 2010-04-30 | ノバルティス アーゲー | Dpp−iv阻害剤としての1−アミノメチル−1−フェニル−シクロヘキサン誘導体 |
NZ579892A (en) | 2007-03-30 | 2012-03-30 | Sanofi Aventis | Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors |
KR20100016073A (ko) * | 2007-04-02 | 2010-02-12 | 인스티튜트 포 원월드 헬스 | Cftr 억제제 화합물 및 이의 용도 |
-
2008
- 2008-03-27 NZ NZ579892A patent/NZ579892A/en not_active IP Right Cessation
- 2008-03-27 CA CA2682629A patent/CA2682629C/fr not_active Expired - Fee Related
- 2008-03-27 BR BRPI0809974-0A2A patent/BRPI0809974A2/pt not_active IP Right Cessation
- 2008-03-27 ES ES08744426T patent/ES2400622T3/es active Active
- 2008-03-27 CN CN2008800100835A patent/CN101646656B/zh active Active
- 2008-03-27 PT PT87444261T patent/PT2142516E/pt unknown
- 2008-03-27 SG SG2012015442A patent/SG179437A1/en unknown
- 2008-03-27 MX MX2009009443A patent/MX2009009443A/es active IP Right Grant
- 2008-03-27 AU AU2008232771A patent/AU2008232771B2/en not_active Ceased
- 2008-03-27 RU RU2009140149/04A patent/RU2464262C2/ru not_active IP Right Cessation
- 2008-03-27 JP JP2010501206A patent/JP5427769B2/ja not_active Expired - Fee Related
- 2008-03-27 DK DK08744426.1T patent/DK2142516T3/da active
- 2008-03-27 EP EP08744426A patent/EP2142516B1/fr active Active
- 2008-03-27 KR KR1020097022868A patent/KR20090125852A/ko not_active Application Discontinuation
- 2008-03-27 WO PCT/US2008/058347 patent/WO2008121670A1/fr active Application Filing
- 2008-03-27 MY MYPI20093870A patent/MY154895A/en unknown
- 2008-03-27 PE PE2008000555A patent/PE20090552A1/es not_active Application Discontinuation
- 2008-03-28 TW TW097111155A patent/TWI430994B/zh not_active IP Right Cessation
- 2008-03-28 AR ARP080101297A patent/AR065874A1/es unknown
- 2008-03-28 PA PA20088774101A patent/PA8774101A1/es unknown
- 2008-03-28 CL CL200800911A patent/CL2008000911A1/es unknown
-
2009
- 2009-09-02 ZA ZA200906082A patent/ZA200906082B/xx unknown
- 2009-09-13 IL IL200898A patent/IL200898A/en not_active IP Right Cessation
- 2009-09-30 US US12/570,355 patent/US8258130B2/en active Active
- 2009-10-22 MA MA32299A patent/MA31326B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0809974A2 (pt) | 2014-10-07 |
AR065874A1 (es) | 2009-07-08 |
IL200898A0 (en) | 2010-05-17 |
CL2008000911A1 (es) | 2008-10-03 |
PE20090552A1 (es) | 2009-06-01 |
AU2008232771B2 (en) | 2012-12-20 |
TWI430994B (zh) | 2014-03-21 |
WO2008121670A1 (fr) | 2008-10-09 |
KR20090125852A (ko) | 2009-12-07 |
PA8774101A1 (es) | 2008-11-19 |
ES2400622T3 (es) | 2013-04-11 |
CA2682629A1 (fr) | 2008-10-09 |
ZA200906082B (en) | 2010-06-30 |
SG179437A1 (en) | 2012-04-27 |
RU2009140149A (ru) | 2011-05-10 |
PT2142516E (pt) | 2013-03-07 |
CA2682629C (fr) | 2013-03-19 |
JP5427769B2 (ja) | 2014-02-26 |
IL200898A (en) | 2013-12-31 |
TW200906802A (en) | 2009-02-16 |
EP2142516A1 (fr) | 2010-01-13 |
CN101646656A (zh) | 2010-02-10 |
US8258130B2 (en) | 2012-09-04 |
AU2008232771A1 (en) | 2008-10-09 |
JP2010523494A (ja) | 2010-07-15 |
EP2142516B1 (fr) | 2012-12-26 |
US20100048568A1 (en) | 2010-02-25 |
RU2464262C2 (ru) | 2012-10-20 |
MY154895A (en) | 2015-08-14 |
MX2009009443A (es) | 2009-09-14 |
CN101646656B (zh) | 2013-08-14 |
DK2142516T3 (da) | 2013-04-15 |
NZ579892A (en) | 2012-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31326B1 (fr) | Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds | |
MA29925B1 (fr) | Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds | |
MA35285B1 (fr) | Indazoles | |
MA30289B1 (fr) | Dérivés d'amines | |
WO2005121130A3 (fr) | Composes pour le traitement de troubles inflammatoires | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
NO20063761L (no) | Sulfonamidderivater for behandling av sykdommer | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
SE0403006D0 (sv) | New compounds | |
WO2008045393A3 (fr) | Composés d'imidazo- et de triazolo-pyridine et leurs procédés d'utilisation | |
NO20055854L (no) | (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister | |
TW200616620A (en) | Compounds for the treatment of inflammatory disorders | |
MX2009008773A (es) | Derivados de 3,4-dihidro-1,4-benzoxazina,3,4-dihidro-1,4-benzotiaz ina y 1,2,3,4-tetrahidro-quinoxalina como agonistas de adrenoreceptores alfa2c. | |
MA27725A1 (fr) | Benzopyrannes utiles pour le traitement d'etats inflammatoires | |
NO20065984L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
NO20065983L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
MX2010005861A (es) | Agonistas novedosos de los receptores de glucocorticoides. | |
TN2009000112A1 (fr) | Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques | |
MA30006B1 (fr) | Composes anti-hypercholesterolemiques | |
EA200601462A1 (ru) | Соединения для лечения заболеваний | |
MA32191B1 (fr) | Inhibiteurs du recepteur de chimiokine cxcr3 | |
MA54386B1 (fr) | Modulateurs de trex1 | |
MA30703B1 (fr) | Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii. | |
MA30037B1 (fr) | Compositions et procedes destines au traitement des troubles du snc |